Bayer’s tumor-agnostic cancer drug gets European nod
Bayer said Monday that the European Medicines Agency had approved Vitrakvi for NTRK fusion-positive cancers. The drug won U.S. Food and Drug Administration accelerated approval in November.
Roche drug is third to win biomarker-driven cancer approval from FDA
On Thursday, Roche’s Rozlytrek won simultaneous FDA labels for NTRK fusion-positive solid tumors and ROS1-positive non-small cell lung cancer.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Japanese regulators say ‘engage’ on Roche’s Trk inhibitor
The FDA is expected to reach a decision by August on the drug, Rozlytrek, a tumor-agnostic cancer drug and potential competitor to Bayer's Vitrakvi.
Lilly and Bayer’s LOXO-195 shows efficacy in TRK inhibitor-resistant tumors at AACR
Among 29 patients, the drug - designed for patients who become resistant to TRK inhibitors like Vitrakvi - showed a 34 percent response rate, according to Phase I data.
If FDA says ‘make it so,’ Loxo’s Vitrakvi could see competition from Roche’s entrectinib
The agency set an August PDUFA date for entrectinib, which it gave priority review. It did the same for another Roche drug, polatuzumab vedotin, for high-grade lymphoma.
FDA approval puts Loxo, Bayer’s Vitrakvi on the rails to value-based care
That the drug will only be given to patients shown through testing to harbor a genetic anomaly that increases the odds of a response makes its approval an important milestone in the evolution of value-based care.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Loxo, Bayer’s Vitrakvi wins FDA approval. Now comes the hard part: finding patients
An oncologist compared NTRK fusion patients to a needle in a haystack, but had some clues of how to find them. Still, drugs like Vitrakvi call for genomic sequencing of all cancer patients, he said.
Loxo, Bayer biomarker-driven drug maintains high response rates in ESMO presentation
Larotrectinib showed an 81 percent response rate among 109 patients with NTRK fusion-positive cancers, with most continuing to respond or receiving surgery with curative intent after more than a year.
New approaches to oncology may require new approaches to clinical trials
Targeted therapies have potential to be highly effective. The challenge is finding patients to enroll in clinical trials.